According to the National Cancer Institute, the average woman has a 12.4% chance of developing breast cancer in her lifetime. There are a number of different factors that can increase a woman’s chances of developing the disease, including several environmental ones such as certain pesticides or industrial chemicals, which means you may be more likely to develop breast cancer depending on where you live.

The St. Louis Dispatch recently took a look at the most recent data from the National Cancer Institute (from 2014) to determine which states have a higher incidence of breast cancer than others.

Topping the list was Washington D.C. The nation’s capital had 143.5 cases of breast cancer per 100,000 people, with the average number of cases per year coming in at 478. Second, was New Hampshire, which had 140.4 cases per 100k people, with an average number of cases per year coming in at 1,183.

Here’s a rundown of the top ten. Check out the full list here:

1. Washington D.C
   
2. New Hampshire
   
3. Connecticut
   
4. Massachusetts
   
5. Hawaii
   
6. Washington
   
7. Delaware
   
8. New Jersey
   
9. Maryland
   
10. South Dakota
    

Read the original article by Emily Price.

From time to time, patients need information about priming topiclicks or reconstituting HCG or Sermorelin.  To save patients the aggravation of waiting on the phone, APS Pharmacy has posted the solutions to several of the common patient questions on our website: 

http://www.myapsmeds.com/faqs-patient-resources

1. Injection Instructions - Reconstitution Required
2. Injection Instructions - Reconstitution Not Required
3. HCG Patient Mixing Instructions
4. Sermorelin Patient Mixing Instructions
5. Topiclick Instructions
6. Vaginal Dosing Kit User Instructions

The U.S. Food and Drug Administration said on Monday that it had approved Otsuka Pharmaceutical Co Ltd’s Abilify MyCite, the first drug with a digital ingestion tracking system to be approved in the United States.

The product, which uses digital tracking to record if the medication was taken, has been approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults, the FDA said.

The system sends a message from the pill’s sensor to a wearable patch, which then transmits the information to a mobile application, so that patients can track the ingestion of the medication on their smartphone.

Abilify MyCite is not approved to treat patients with dementia-related psychosis and contains a boxed warning alerting health care professionals that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.

The ingestible sensor used in Abilify MyCite was first permitted for marketing by the FDA in 2012.

Read the original article by Reuters Staff.